Cargando…

Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men

Purpose: Few studies have evaluated the risk profile of prostate-specific antigen (PSA)-detected T1cN0M0 prostate cancer, defined as tumors diagnosed by needle biopsy because of elevated PSA levels without other clinical signs of disease. However, some men with stage T1cN0M0 prostate cancer may have...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hong, Messing, Edward M., Travis, Lois B., Hyrien, Ollivier, Chen, Rui, Milano, Michael T., Chen, Yuhchyau
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870291/
https://www.ncbi.nlm.nih.gov/pubmed/24392353
http://dx.doi.org/10.3389/fonc.2013.00312
_version_ 1782296687802318848
author Zhang, Hong
Messing, Edward M.
Travis, Lois B.
Hyrien, Ollivier
Chen, Rui
Milano, Michael T.
Chen, Yuhchyau
author_facet Zhang, Hong
Messing, Edward M.
Travis, Lois B.
Hyrien, Ollivier
Chen, Rui
Milano, Michael T.
Chen, Yuhchyau
author_sort Zhang, Hong
collection PubMed
description Purpose: Few studies have evaluated the risk profile of prostate-specific antigen (PSA)-detected T1cN0M0 prostate cancer, defined as tumors diagnosed by needle biopsy because of elevated PSA levels without other clinical signs of disease. However, some men with stage T1cN0M0 prostate cancer may have high-risk disease (HRD), thus experiencing inferior outcomes as predicted by a risk group stratification model. Methods: We identified men diagnosed with stage T1cN0M0 prostate cancer from 2004 to 2008 reported to the surveillance, epidemiology, and end results (SEER) program. Multivariate logistic regression was used to model the probability of intermediate-risk-disease (IRD) (PSA ≥ 10 ng/ml but <20 ng/ml and/or GS 7), and high-risk-disease (HDR) (PSA ≥ 20 ng/ml, and/or GS ≥ 8), relative to low-risk disease (LRD) (PSA < 10 ng/ml and GS ≤ 6), adjusting for age, race, marital status, median household income, and area of residence. Results: A total of 70,345 men with PSA-detected T1cN0M0 prostate cancer were identified. Of these, 47.6, 35.9, and 16.5% presented with low-, intermediate-, and high-risk disease, respectively. At baseline (50 years of age), risk was higher for black men than for whites for HRD (OR 3.31, 95% CI 2.85–3.84). The ORs for age (per year) for HRD relative to LRD were 1.09 (95% CI 1.09–1.10) for white men, and as 1.06 (95% CI 1.05–1.07) for black men. Further, among a subgroup of men with low PSA (<10 ng/ml) T1cN0M0 prostate cancer, risk was also higher for black man than for white men at baseline (50 years of age) (OR 2.70, 95% CI 2.09–3.48). The ORs for age (per year) for HRD relative to LRD were 1.09 (95% CI 1.09–1.10) for white men, and as 1.06 (95% CI 1.05–1.07) for black men. Conclusion: A substantial proportion of men with PSA-detected prostate cancer as reported to the SEER program had HRD. Black race and older age were associated with a greater likelihood of HRD.
format Online
Article
Text
id pubmed-3870291
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-38702912014-01-03 Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men Zhang, Hong Messing, Edward M. Travis, Lois B. Hyrien, Ollivier Chen, Rui Milano, Michael T. Chen, Yuhchyau Front Oncol Oncology Purpose: Few studies have evaluated the risk profile of prostate-specific antigen (PSA)-detected T1cN0M0 prostate cancer, defined as tumors diagnosed by needle biopsy because of elevated PSA levels without other clinical signs of disease. However, some men with stage T1cN0M0 prostate cancer may have high-risk disease (HRD), thus experiencing inferior outcomes as predicted by a risk group stratification model. Methods: We identified men diagnosed with stage T1cN0M0 prostate cancer from 2004 to 2008 reported to the surveillance, epidemiology, and end results (SEER) program. Multivariate logistic regression was used to model the probability of intermediate-risk-disease (IRD) (PSA ≥ 10 ng/ml but <20 ng/ml and/or GS 7), and high-risk-disease (HDR) (PSA ≥ 20 ng/ml, and/or GS ≥ 8), relative to low-risk disease (LRD) (PSA < 10 ng/ml and GS ≤ 6), adjusting for age, race, marital status, median household income, and area of residence. Results: A total of 70,345 men with PSA-detected T1cN0M0 prostate cancer were identified. Of these, 47.6, 35.9, and 16.5% presented with low-, intermediate-, and high-risk disease, respectively. At baseline (50 years of age), risk was higher for black men than for whites for HRD (OR 3.31, 95% CI 2.85–3.84). The ORs for age (per year) for HRD relative to LRD were 1.09 (95% CI 1.09–1.10) for white men, and as 1.06 (95% CI 1.05–1.07) for black men. Further, among a subgroup of men with low PSA (<10 ng/ml) T1cN0M0 prostate cancer, risk was also higher for black man than for white men at baseline (50 years of age) (OR 2.70, 95% CI 2.09–3.48). The ORs for age (per year) for HRD relative to LRD were 1.09 (95% CI 1.09–1.10) for white men, and as 1.06 (95% CI 1.05–1.07) for black men. Conclusion: A substantial proportion of men with PSA-detected prostate cancer as reported to the SEER program had HRD. Black race and older age were associated with a greater likelihood of HRD. Frontiers Media S.A. 2013-12-23 /pmc/articles/PMC3870291/ /pubmed/24392353 http://dx.doi.org/10.3389/fonc.2013.00312 Text en Copyright © 2013 Zhang, Messing, Travis, Hyrien, Chen, Milano and Chen. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhang, Hong
Messing, Edward M.
Travis, Lois B.
Hyrien, Ollivier
Chen, Rui
Milano, Michael T.
Chen, Yuhchyau
Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men
title Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men
title_full Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men
title_fullStr Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men
title_full_unstemmed Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men
title_short Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men
title_sort age and racial differences among psa-detected (ajcc stage t1cn0m0) prostate cancer in the u.s.: a population-based study of 70,345 men
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870291/
https://www.ncbi.nlm.nih.gov/pubmed/24392353
http://dx.doi.org/10.3389/fonc.2013.00312
work_keys_str_mv AT zhanghong ageandracialdifferencesamongpsadetectedajccstaget1cn0m0prostatecancerintheusapopulationbasedstudyof70345men
AT messingedwardm ageandracialdifferencesamongpsadetectedajccstaget1cn0m0prostatecancerintheusapopulationbasedstudyof70345men
AT travisloisb ageandracialdifferencesamongpsadetectedajccstaget1cn0m0prostatecancerintheusapopulationbasedstudyof70345men
AT hyrienollivier ageandracialdifferencesamongpsadetectedajccstaget1cn0m0prostatecancerintheusapopulationbasedstudyof70345men
AT chenrui ageandracialdifferencesamongpsadetectedajccstaget1cn0m0prostatecancerintheusapopulationbasedstudyof70345men
AT milanomichaelt ageandracialdifferencesamongpsadetectedajccstaget1cn0m0prostatecancerintheusapopulationbasedstudyof70345men
AT chenyuhchyau ageandracialdifferencesamongpsadetectedajccstaget1cn0m0prostatecancerintheusapopulationbasedstudyof70345men